logo
AI Icon𝛼SK or Search
ENTITY

TuHURA Biosciences (HURA US)

11
Analysis
Health Care • United States
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company. The Company focuses on developing technologies to overcome resistance to cancer immunotherapy. TuHURA Biosciences operates in the United States.
more
bullish•TuHURA Biosciences
•22 Dec 2025 23:00•Issuer-paid

HURA: Focus on the Delta Opioid Receptor

TuHURA is a clinical-stage, oncology-focused biotechnology company advancing innate immune agonists, checkpoint inhibitors & antibody-drug...

Logo
Share
bullish•TuHURA Biosciences
•18 Nov 2025 06:00•Issuer-paid

HURA: Third Quarter Results

TuHURA is a clinical-stage, oncology-focused biotechnology company advancing innate immune agonists, checkpoint inhibitors & antibody-drug...

Logo
Share
bullish•TuHURA Biosciences
•21 Aug 2025 22:00•Issuer-paid

HURA: IFx-2.0 Phase III Begins

TuHURA is a clinical-stage, oncology-focused biotechnology company advancing innate immune agonists, checkpoint inhibitors & antibody-drug...

Logo
Share
bullish•TuHURA Biosciences
•19 May 2025 22:00•Issuer-paid

HURA: First Quarter 2025 Results

TuHURA is a clinical-stage, oncology-focused biotechnology company advancing innate immune agonists, checkpoint inhibitors & antibody-drug...

Logo
Share
bullish•TuHURA Biosciences
•14 Apr 2025 22:00•Issuer-paid

HURA: 2024 Financial Results

TuHURA is a clinical-stage, oncology-focused biotechnology company advancing innate immune agonists, checkpoint inhibitors & antibody-drug...

Logo
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x